Taro Pharmaceutical Industries Ltd. announced that it has been authorized for listing on the New York Stock Exchange (NYSE). The Company's ordinary shares began trading on March 22, 2012, under the symbol “TARO.”
Sun Pharma acquired a controlling interest in Taro in September 2010.
The TaroPharma branded division is established to promote proprietary prescription and over-the-counter products in the U.S. and Canada.
Warfarin Sodium Tablets, the generic form of Coumadin®, are approved for sale in the U.S. and later in Canada (2000) and the UK (2002). Taro manufactures its own Warfarin API.
Taro makes a commitment to a research-based business model, with the goal of generating a stream of new product approvals through investment in its own R&D programs.
Taro enters the U.S. market with its first FDA-approved topical product.
Taro established topical product operations in Brampton, allowing entry into the North American generic pharmaceutical market.
Taro shares are listed on The Nasdaq Stock Market. The Company’s total market capitalization is under $5 million.
Taro becomes a public company through a 1961 Initial Public Offering (IPO)
Taro launches a chemical synthesis program to produce API’s from raw chemicals, allowing the company to manufacture both the API and finished dosage form for many of its key medications to tightly control quality and consistency of supply.
Taro acquires the rights to the Coumadin®* in Israel.
Taro Pharmaceutical Industries Ltd was established in Israel to develop pharmaceutical products.
* In Canada, Coumadin is a trademark of the Bristol-Myers Squibb Company.